A Randomized Study to Evaluate the Bioavailability of BMS-986141 From a Form B Tablet Formulation Relative to the Form A Reference Tablet in Healthy Participants

Trial Profile

A Randomized Study to Evaluate the Bioavailability of BMS-986141 From a Form B Tablet Formulation Relative to the Form A Reference Tablet in Healthy Participants

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs BMS 986141 (Primary)
  • Indications Thrombosis
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 21 Mar 2018 Planned end date has been changed from 1 Mar 2018 to 7 Feb 2017
    • 21 Mar 2018 Planned primary completion date has been changed from 1 Mar 2018 to 7 Feb 2017.
    • 21 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top